Semaglutide has shown kidney protection in large trials, most clearly in people with type 2 diabetes and chronic kidney disease. GLP-1 medications can also stress the kidneys if vomiting or diarrhea cause dehydration, so hydration and lab monitoring matter.
GLP-1 medications and the kidneys have a two-sided relationship. On the protective side, semaglutide lowered the risk of serious kidney outcomes in a large trial of people with type 2 diabetes and chronic kidney disease, and it showed a smaller kidney benefit in people with obesity and heart disease but no diabetes. On the caution side, the vomiting and diarrhea these medications can cause may lead to dehydration, which has been linked to acute kidney injury. Knowing both sides helps you and your provider decide what to watch.
Chronic kidney disease (CKD) means the kidneys are damaged and, over time, may not clean the blood as well as they should. The CDC explains that when kidneys do not work well, waste and extra fluid build up, which may lead to high blood pressure, heart disease, stroke and early death.
CDC estimates updated in 2026 show how common it is and how often it overlaps with metabolic conditions:
Because so many people are unaware, testing is the only reliable way to know where you stand.
NIDDK describes two core tests:
| Test | What it measures | Result that may suggest kidney disease |
|---|---|---|
| GFR (estimated from blood creatinine) | How well the kidneys filter blood | Below 60; 15 or less is classified as kidney failure |
| Urine albumin-to-creatinine ratio (UACR) | Albumin, a protein, leaking into urine | More than 30 mg/g |
NIDDK notes that an abnormal urine result may be repeated one or two more times to confirm it. People with diabetes should be checked every year, and people with high blood pressure, heart disease or a family history of kidney failure should ask their provider how often to be tested.
If you are considering a GLP-1 medication, having a recent GFR and UACR on file gives your prescriber a baseline to compare against later.
FLOW, published in the New England Journal of Medicine in 2024, was a kidney outcomes trial designed to test semaglutide on kidney disease events. It enrolled 3,533 adults with type 2 diabetes and chronic kidney disease and compared semaglutide (the Ozempic formulation used for diabetes) with placebo. The trial ended early, after a median follow-up of 3.4 years, because stopping was recommended at a prespecified interim analysis.
Compared with placebo, semaglutide was associated with:
Serious adverse events were reported in a lower share of participants on semaglutide (49.6 percent) than on placebo (53.8 percent). Based on FLOW, the FDA expanded the Ozempic label in January 2025 to include reducing the risk of sustained GFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
The SELECT trial enrolled adults with overweight or obesity and established cardiovascular disease, but no diabetes, and tested semaglutide at the weight management dose. A 2024 kidney analysis in Nature Medicine reported:
The authors described these results as suggesting a kidney benefit in this population. Note that the absolute numbers are small because few participants had kidney events at all. Wegovy does not carry a kidney indication, and neither does Zepbound; tirzepatide's approved uses are weight management and obstructive sleep apnea in adults with obesity.
The Wegovy and Zepbound prescribing information both include a warning about acute kidney injury. Both note postmarketing reports of acute kidney injury, in some cases requiring hemodialysis. The Wegovy label adds that most cases occurred in people who had gastrointestinal reactions leading to dehydration, and both labels advise monitoring kidney function in people with side effects that could cause fluid loss.
In practical terms:
FLOW and SELECT tested FDA-approved semaglutide. Compounded semaglutide and tirzepatide are not FDA-approved, and their kidney effects have not been studied in these trials. Compounded products available through NewDay Wellness are prescribed by licensed providers and dispensed by licensed US pharmacies, but they are still not FDA-approved. Dosing is always set by your prescriber.
Semaglutide was studied specifically in people with type 2 diabetes and chronic kidney disease in the FLOW trial, where it reduced kidney and cardiovascular events. Whether any GLP-1 is right for you depends on your kidney function, other conditions and medications, which a licensed provider needs to review.
The main documented risk is acute kidney injury after dehydration, usually from vomiting or diarrhea. The labels report this from postmarketing experience, sometimes severe enough to require dialysis. Staying hydrated and reporting persistent gastrointestinal symptoms lowers that risk.
Tirzepatide does not currently have an FDA-approved kidney indication. Its approved uses are weight management and obstructive sleep apnea in adults with obesity. Kidney outcomes for tirzepatide should be discussed with your provider as the research develops.
Ask about an estimated GFR, which is a blood test, and a urine albumin-to-creatinine ratio. NIDDK describes these as the two main tests for chronic kidney disease, and having baseline results helps track changes over time.
If you have diabetes, high blood pressure or a family history of kidney failure, share your kidney test results with a licensed provider before starting a weight management medication. They can weigh the potential benefits against your individual risks and set a plan for monitoring. This article is educational and does not determine eligibility for any treatment.
Written by the NewDay Wellness editorial team from the sources above and checked against them before publication, and medically reviewed by Dr. Sean Arora and Dr. Shannon Arora of Arora Health & Aesthetics; see our editorial standards. This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
You can travel, celebrate and eat out on a GLP-1 medication with some planning: keep medication in your carry-on and follow your pharmacy's storage instructions, order smaller portions, keep fluids up, and ask your prescriber how to handle timing changes.
Read article
The first weeks on a GLP-1 usually mean a low starting dose that your prescriber raises gradually, a quieter appetite, and for many people mild to moderate digestive side effects. Knowing what is common and what to report makes the start easier.
Read articleWhen appetite drops, the quality of each meal matters more. A practical guide to protein, fiber, fluids and micronutrients while taking a GLP-1 medication, drawn from published clinical guidance.
Read article